GPC Biotech reports encouraging preclinical results from cancer study

The data show that RGB-286638 demonstrates in vivo activity in several preclinical models of multiple myeloma. The compound also induces cell death in multiple myeloma cells independent from the p53 status; p53 is a gene involved in the control of cell proliferation.

Additionally, preclinical data on RGB-286638 in solid tumor cell lines demonstrate that it induces rapid tumor cell killing at very low doses. Also, RGB-286638 shows a potent profile of activities across a broad range of solid tumor cell lines, including cell lines originated from prostate, pancreas and kidney cancers, the company said.

A Phase I trial evaluating RGB-286638 in patients with advanced solid tumors is currently underway in Europe. RGB-286638 is a multi-targeted protein kinase inhibitor currently in Phase I clinical testing.